Cambridge Investment Research Advisors
IRMD icon

Cambridge Investment Research Advisors’s iRadimed IRMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Buy
2,920
+259
+10% +$23.6K ﹤0.01% 3510
2026
Q1 		$256K Buy
2,661
+231
+10% +$23.1K ﹤0.01% 3424
2025
Q4 		$236K Buy
+2,430
New +$208K ﹤0.01% 3427

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors's IRMD Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its iRadimed (IRMD) stake by 9.7% in Q2 2026, buying an estimated $23.6K and bringing the position to 2,920 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #3510.

Cambridge Investment Research Advisors first reported a position in IRMD in Q4 2025 and has held it in 3 quarters since. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Cambridge Investment Research Advisors held 2,920 shares of iRadimed worth $279K as of Q2 2026.
  • Cambridge Investment Research Advisors bought 259 iRadimed shares in Q2 2026, an estimated $23.6K.
  • iRadimed made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3510 holding.
  • Cambridge Investment Research Advisors first reported a position in iRadimed in Q4 2025 and has held it in 3 quarters since.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.